Inflammation and coagulation

Critical Care Medicine

Volumn 38, Issue SUPPL. 2, 2010, Pages

  Levi, Marcel ^a   Van Der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Coagulation; Fibrin; Fibrinolysis; Glycocalyx; Inflammation

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 7A; ENDOTHELIAL PROTEIN C RECEPTOR; FIBRIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; PLASMIN; PLASMINOGEN; PROTEINASE ACTIVATED RECEPTOR; THROMBOMODULIN; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA;

BLOOD CLOTTING DISORDER; FIBRIN DEPOSITION; FIBRINOLYSIS; GLYCOCALYX; HUMAN; INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SEPSIS; THROMBOCYTOPENIA;

EID: 74949117097     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181c98d21     Document Type: Review

References (128)

1. Levi M, Opal SM: Coagulation abnormalities in critically ill patients. Crit Care 2006; 10: 222-228
2. Levi M, ten Cate H, van der Poll T, et al: Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993; 270: 975-979
3. Levi M, ten Cate H: Disseminated intravas-cular coagulation. N Engl J Med 1999; 341: 586-592
4. Colman RW, Robboy SJ, Minna JD: Disseminated intravascular coagulation: A reappraisal. Annu Rev Med 1979; 30:359-374
5. Levi M, ten Cate H, van der Poll T: Endo-thelium: Interface between coagulation and inflammation. Crit Care Med 2002; 30: S220-S224
6. Levi M, Marder VJ: Coagulation abnormalities in sepsis. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Colman RW, Marder VJ, Clowes AW, et al (Eds). Philadelphia, Lippincott Williams & Wilkins, 2006, pp 1601-1613
7. Aderem A, Ulevitch RJ: Toll-like receptors in the induction of the innate immune response. Nature 2000; 406:782-787
8. Opal SM, Esmon CT: Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogen-esis of sepsis. Crit Care 2003; 7:23-38
9. Libby P, Aikawa M: Stabilization of atherosclerotic plaques: New mechanisms and clinical targets. Nat Med 2002; 8:1257-1262
10. van der Poll T, Levi M, Hack CE, et al: Elimination of interleukin 6 attenuates coagulation activation in experimental endo-toxemia in chimpanzees. J Exp Med 1994; 179:1253-1259
11. van Deventer SJ, Buller HR, ten Cate JW, et al: Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990; 76:2520-2526
12. Boermeester MA, van LP, Coyle SM, et al: Interleukin-1 blockade attenuates mediator release and dysregulation of the hemostatic mechanism during human sepsis. Arch Surg 1995; 130:739-748
13. Aird WC: Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis. Crit Care Med 2001; 29:S28-S34
14. Levi M, Keller TT, van Gorp E, ten Cate H: Infection and inflammation and the coagu-lation system. Cardiovasc Res 2003; 60: 26-39
15. Robboy SJ, Major MC, Colman RW, et al: Pathology of disseminated intravascular coagulation (DIC). Analysis of 26 cases. Hum Pathol 1972; 3:327-343
16. Shimamura K, Oka K, Nakazawa M, et al: Distribution patterns of microthrombi in disseminated intravascular coagulation. Arch Pathol Lab Med 1983; 107:543-547
17. Coalson JJ: Pathology of sepsis, septic shock, and multiple organ failure. Perspective on sepsis and septic shock. Fullerton, CA, Society of Critical Care Medicine, 1986, pp 27-59
18. Creasey AA, Chang AC, Feigen L, et al: Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993; 91:2850-2856
19. Kessler CM, Tang Z, Jacobs HM, et al: The suprapharmacologic dosing of antithrom-bin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: Substantial reduction in mortality and morbidity. Blood 1997; 89: 4393-4401
20. Taylor FBJ, Chang A, Ruf W, et al: Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991; 33:127-134
21. Taylor FBJ, Chang A, Esmon CT, et al: Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987; 79:918-925
22. Welty-Wolf KE, Carraway MS, Miller DL, et al: Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am J Respir Crit Care Med 2001; 164:1988-1996
23. Miller DL, Welty-Wolf K, Carraway MS, et al: Extrinsic coagulation blockade attenuates lung injury and proinflammatory cyto-kine release after intratracheal lipopolysac-charide. Am J Respir Cell Mol Biol 2002; 26:650-658
24. Fourrier F, Chopin C, Goudemand J, et al: Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992; 101:816-823
25. Dhainaut JF, Yan SB, Joyce DE, et al: Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004; 2:1924-1933
26. Levi M, Lowenberg EC: Thrombocytopenia in critically ill patients. Semin Thromb He-most 2008; 34:417-424
27. Vanderschueren S, De Weerdt A, Malbrain M, et al: Thrombocytopenia and prognosis in intensive care. Crit Care Med 2000; 28: 1871-1876
28. Strauss R, Wehler M, Mehler K, et al: Thrombocytopenia in patients in the medical intensive care unit: Bleeding prevalence, transfusion requirements, and outcome. Crit Care Med 2002; 30:1765-1771
29. Oppenheim-Eden A, Glantz L, Eidelman LA, et al: Spontaneous intracerebral hemorrhage in critically ill patients: Incidence over six years and associated factors. Intensive Care Med 1999; 25:63-67
30. Stephan F, Hollande J, Richard O, et al: Thrombocytopenia in a surgical ICU. Chest 1999; 115:1363-1370
31. Akca S, Haji Michael P, de Medonca A, et al: The time course of platelet counts in critically ill patients. Crit Care Med 2002; 30: 753-756
32. Chakraverty R, Davidson S, Peggs K, et al: The incidence and cause of coagulopathies in an intensive care population. Br J Haematol 1996; 93:460-463
33. MacLeod JB, Lynn M, McKenney MG, et al: Early coagulopathy predicts mortality in trauma. J Trauma 2003; 55:39-44
34. Esmon CT: The regulation of natural anticoagulant pathways. Science 1987; 235: 1348-1352
35. Levi M, van der Poll T, ten Cate H: Tissue factor in infection and severe inflammation. Semin Thromb Hemost 2006; 32:33-39
36. Levi M, ten Cate H, Bauer KA, et al: Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifyl-line or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994; 93:114-120
37. Levi M, van der Poll T, ten Cate H, et al: The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Invest 1997; 27:3-9
38. Osterud B, Rao LV, Olsen JO: Induction of tissue factor expression in whole blood-lack of evidence for the presence of tissue factor expression on granulocytes. Thromb Hae-most 2000; 83:861-867
39. Franco RF, de Jonge E, Dekkers PE, et al: The in vivo kinetics of tissue factor messenger RNA expression during human endotox-emia: Relationship with activation of coagulation. Blood 2000; 96:554-559
40. Rauch U, Bonderman D, Bohrmann B, et al: Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 2000; 96:170-175
41. Osterud B, Bjorklid E: Sources of tissue factor. Semin Thromb Hemost 2006; 32: 11-23
42. Osterud B: Tissue factor expression by monocytes: regulation and pathophysiolog-ical roles. Blood Coagul Fibrinolysis 1998; 9(Suppl 1):S9-S14
43. Furie B, Furie BC: Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med 2004; 10:171-178
44. Neumann FJ, Marx N, Gawaz M, et al: Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation 1997; 95:2387-2394 (Pubitemid 27224733)
45. Levi M, van der Poll T: The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Semin Thromb Hemost 2008; 34: 459-468
46. Levi M: Antithrombin in sepsis revisited. Crit Care 2005; 9:624-625
47. Levi M, van der Poll T, Buller HR: Bidirectional relation between inflammation and coagulation. Circulation 2004; 109: 2698-2704
48. Kobayashi M, Shimada K, Ozawa T: Human recombinant interleukin-1 beta-and tumor necrosis factor alpha-mediated suppression of heparin-like compounds on cultured porcine aortic endothelial cells. J Cell Physiol 1990; 144:383-390
49. Levi M, van der Poll T: Recombinant human activated protein C: Current insights into its mechanism of action. Crit Care 2007; 11(Suppl 5):S3
50. Esmon CT: Role of coagulation inhibitors in inflammation. Thromb Haemost 2001; 86: 51-56
51. Levi M, de Jonge E, van der Poll T: Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med 2001; 29(7 Suppl):S90-S94
52. Esmon CT: The endothelial cell protein C receptor. Thromb Haemost 2000; 83: 639-643
53. Perez-Casal M, Downey C, Fukudome K, et al: Activated protein C induces the release of microparticle-associated endothelial protein C receptor. Blood 2005; 105:1515-1522
54. Mesters RM, Helterbrand J, Utterback BG, et al: Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med 2000; 28:2209-2216
55. Vary TC, Kimball SR: Regulation of hepatic protein synthesis in chronic inflammation and sepsis. Am J Physiol 1992; 262: C445-C452
56. Eckle I, Seitz R, Egbring R, et al: Protein C degradation in vitro by neutrophil elastase. Biol Chem Hoppe Seyler 1991; 372: 1007-1013
57. Nawroth PP, Stern DM: Modulation of en-dothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740-745
58. Faust SN, Levin M, Harrison OB, et al: Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001; 345:408-416 (Pubitemid 32747604)
59. Garcia de Frutos P, Alim RI, Hardig Y, et al: Differential regulation of alpha and beta chains of C4b-binding protein during acute-phase response resulting in stable plasma levels of free anticoagulant protein S. Blood 1994; 84:815-822
60. Taylor FBJ, Dahlback B, Chang AC, et al: Role of free protein S and C4b binding protein in regulating the coagulant response to Escherichia coli. Blood 1995; 86:2642-2652
61. Taylor FBJ, Stearns-Kurosawa DJ, Kuro-sawa S, et al: The endothelial cell protein C receptor aids in host defense against Esch-erichia coli sepsis. Blood 2000; 95: 1680-1686
62. De Pont AC, Bakhtiari K, Hutten BA, et al: Endotoxaemia induces resistance to activated protein C in healthy humans. Br J Haematol 2006; 134:213-219
63. de Jonge E, Dekkers PE, Creasey AA, et al: Tissue factor pathway inhibitor (TFPI) dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cy-tokine response during human endotox-emia. Blood 2000; 95:1124-1129
64. Biemond BJ, Levi M, ten Cate H, et al: Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: Effect of interventions in the cytokine and coagulation cascades. Clin Sci (Lond) 1995; 88:587-594
65. van der Poll T, Levi M, Buller HR, et al: Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 1991; 174:729-732
66. Yamamoto K, Loskutoff DJ: Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plas-minogen activator. J Clin Invest 1996; 97: 2440-2451 (Pubitemid 26187331)
67. Mileno MD, Margolis NH, Clark BD, et al: Coagulation of whole blood stimulates in-terleukin-1 beta gene expression. J Infect Dis 1995; 172:308-311
68. Jones A, Geczy CL: Thrombin and factor Xa enhance the production of interleukin-1. Immunology 1990; 71:236-241
69. Johnson K, Choi Y, DeGroot E, et al: Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J Immunol 1998; 160:5130-5135
70. Sower LE, Froelich CJ, Carney DH, et al: Thrombin induces IL-6 production in fibro-blasts and epithelial cells. Evidence for the involvement of the seven-transmembrane domain (STD) receptor for alpha-thrombin. J Immunol 1995; 155:895-901
71. van der Poll T, de Jonge E, Levi M: Regulatory role of cytokines in disseminated intra-vascular coagulation. Semin Thromb He-most 2001; 27:639-651
72. de Jonge E, Friederich PW, Levi M, et al: Activation of coagulation by administration of recombinant factor VIIa elicits interleu-kin-6 and interleukin-8 release in healthy humen subjects. Clin Diagn Lab Immunol 2003; 10:495-497
73. Coughlin SR: Thrombin signalling and pro-tease-activated receptors. Nature 2000; 407: 258-264
74. Camerer E, Cornelissen I, Kataoka H, et al: Roles of protease-activated receptors in a mouse model of endotoxemia. Blood 2006; 107:3912-3921
75. Slofstra SH, Bijlsma MF, Groot AP, et al: Protease-activated receptor-4 inhibition protects from multiorgan failure in a mu-rine model of systemic inflammation. Blood 2007; 110:3176-3182
76. Sevastos J, Kennedy SE, Davis DR, et al: Tissue factor deficiency and PAR-1 deficiency are protective against renal ischemia reperfusion injury. Blood 2007; 109: 577-583
77. Roemisch J, Gray E, Hoffmann JN, et al: Antithrombin: A new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis 2002; 13:657-670
78. Opal SM: Interactions between coagulation and inflammation. Scand J Infect Dis 2003; 35:545-554
79. Harada N, Okajima K, Kushimoto S, et al: Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin. Blood 1999; 93: 157-164
80. Horie S, Ishii H, Kazama M: Heparin-like glycosaminoglycan is a receptor for anti-thrombin III-dependent but not for throm-bin-dependent prostacyclin production in human endothelial cells. Thromb Res 1990; 59:895-904
81. Mizutani A, Okajima K, Uchiba M, et al: Antithrombin reduces ischemia/reperfu-sion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production. Blood 2003; 101:3029-3036
82. Uchiba M, Okajima K, Murakami K: Effects of various doses of antithrombin III on en-dotoxin-induced endothelial cell injury and coagulation abnormalities in rats. Thromb Res 1998; 89:233-241
83. Esmon CT: New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. J Exp Med 2002; 196:561-564
84. Okajima K: Regulation of inflammatory responses by natural anticoagulants. Immunol Rev 2001; 184:258-274
85. Murakami K, Okajima K, Uchiba M, et al: Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 1996; 87:642-647
86. Hancock WW, Tsuchida A, Hau H, et al: The anticoagulants protein C and protein S display potent antiinflammatory and immuno-suppressive effects relevant to transplant biology and therapy. Transplant Proc 1992; 24:2302-2303
87. Hancock WW, Grey ST, Hau L, et al: Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent prolifer-ative responses. Transplantation 1995; 60:1525-1532
88. White B, Schmidt M, Murphy C, et al: Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol 2000; 110:130-134
89. Levi M, Dorffler-Melly J, Reitsma PH, et al: Aggravation of endotoxin-induced disseminated intravascular coagulation and cyto-kine activation in heterozygous protein C deficient mice. Blood 2003; 101:4823-4827
90. Lay AJ, Donahue D, Tsai MJ, et al: Acute inflammation is exacerbated in mice genetically predisposed to a severe protein C deficiency. Blood 2007; 109:1984-1991
91. Riewald M, Petrovan RJ, Donner A, et al: Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002; 296:1880-1882
92. Ludeman MJ, Kataoka H, Srinivasan Y, et al: PAR1 cleavage and signaling in response to activated protein C and thrombin. J Biol Chem 2005; 280:13122-13128
93. Xu J, Qu D, Esmon NL, et al: Metallopro-teolytic release of endothelial cell protein C receptor. J Biol Chem 2000; 275: 6038-6044
94. Kurosawa S, Esmon CT, Stearns-Kurosawa DJ: The soluble endothelial protein C receptor binds to activated neutrophils: involvement of proteinase-3 and CD11b/CD18. J Immunol 2000; 165:4697-4703
95. Oganesyan V, Oganesyan N, Terzyan S, et al: The crystal structure of the endothelial protein C receptor and a bound phospholipid. J Biol Chem 2002; 277:24851-24854
96. Feistritzer C, Sturn DH, Kaneider NC, et al: Endothelial protein C receptor-dependent inhibition of human eosinophil chemotaxis by protein C. J Allergy Clin Immunol 2003; 112:375-381
97. Sturn DH, Kaneider NC, Feistritzer C, et al: Expression and function of the endothelial protein C receptor in human neutrophils. Blood 2003; 102:1499-1505
98. Hoffmann JN, Vollmar B, Laschke MW, et al: Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia. Crit Care Med 2004; 32: 1011-1017
99. Nick JA, Coldren CD, Geraci MW, et al: Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 2004; 104: 3878-3885
100. Shimizu S, Gabazza EC, Taguchi O, et al: Activated protein C inhibits the expression of platelet-derived growth factor in the lung. Am J Respir Crit Care Med 2003; 167:1416-1426
101. Zeng W, Matter WF, Yan SB, et al: Effect of drotrecogin alfa (activated) on human en-dothelial cell permeability and Rho kinase signaling. Crit Care Med 2004; 32: S302-S308
102. Feistritzer C, Riewald M: Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005; 105:3178-3184
103. Finigan JH, Dudek SM, Singleton PA, et al: Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem 2005; 280: 17286-17293
104. Cheng T, Liu D, Griffin JH, et al: Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003; 9:338-342
105. Mosnier LO, Griffin JH: Inhibition of stau-rosporine-induced apoptosis of endothelial cells by activated protein C requires protease activated receptor-1 and endothelial cell protein C receptor. Biochem J 2003; 373:65-70
106. Mosnier LO, Zlokovic BV, Griffin JH: The cytoprotective protein C pathway. Blood 2007; 109:3161-3172
107. Szaba FM, Smiley ST: Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood 2002; 99:1053-1059
108. Blasi F, Carmeliet P: uPAR: A versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3:932-943
109. Loskutoff DJ, Curriden SA, Hu G, et al: Regulation of cell adhesion by PAI-1. APMIS 1999; 107:54-61
110. Rijneveld AW, Levi M, Florquin S, et al: Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J Immunol 2002; 168: 3507-3511
111. Robson SC, Saunders R, Kirsch RE: Mono-cyte-macrophage release of IL-1 is inhibited by type-1 plasminogen activator inhibitors. J Clin Lab Immunol 1990; 33:83-90
112. Weinbaum S, Zhang X, Han Y, et al: Mech-anotransduction and flow across the endo-thelial glycocalyx. Proc Natl Acad Sci USA 2003; 100:7988-7995
113. Maczewski M, Duda M, Pawlak W, et al: Endothelial protection from reperfusion injury by ischemic preconditioning and dia-zoxide involves a SOD-like anti-O2-mechanism. J Physiol Pharmacol 2004; 55: 537-550
114. Vink H, Constantinescu AA, Spaan JA: Oxidized lipoproteins degrade the endothelial surface layer: Implications for platelet-endothelial cell adhesion. Circulation 2000; 101:1500-1502
115. Nieuwdorp M, van Haeften TW, Gouverneur MC, et al: Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes 2006; 55:480-486
116. van den Berg BM, Vink H, Spaan JA: The endothelial glycocalyx protects against myocardial edema. Circ Res 2003; 92: 592-594
117. Levi M, ten Cate H, van der Poll T: Disseminated intravascular coagulation: State of the art. Thromb Haemost 1999; 82:695-705
118. Warren BL, Eid A, Singer P, et al: Caring for the critically ill patient. High-dose anti-thrombin III in severe sepsis: A randomized controlled trial. JAMA 2001; 286:1869-1878
119. Kienast J, Juers M, Wiedermann CJ, et al: Treatment effects of high-dose antithrom-bin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006; 4:90-97
120. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
121. Vincent JL, Angus DC, Artigas A, et al: Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003; 31:834-840
122. Abraham E, Laterre PF, Garg R, et al: Dro-trecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353:1332-1341
123. Levi M: Activated protein C in sepsis: A critical review. Curr Opin Hematol 2008; 15:481-486
124. Dellinger RP, Levy MM, Carlet JM, et al: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327
125. Wiedermann CJ, Kaneider NC: A meta-analysis of controlled trials of recombinant human activated protein C therapy in patients with sepsis. BMC Emerg Med 2005; 5:7.:7
126. Marti-Carvajal A, Salanti G, Cardona AF: Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev 2007; CD004388
127. Barie PS: "All in" for a huge pot: The PROWESS-SHOCK trial for refractory septic shock. Surg Infect (Larchmt) 2007; 8:491-494
128. Schouten M, Wiersinga WJ, Levi M, et al: Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 2008; 83: 536-545